In 2013, itolizumab received approval in India as a safe and effective treatment for plaque psoriasis. In aGVHD, steroid-insensitive CD6-high T cells contribute to gastrointestinal inflammation ...

Despite missing its primary endpoint, Equillium is pushing ahead with itolizumab citing its complete response by day 99.

Equillium’s phase 3 graft-versus-host disease (GVHD) trial has missed its primary endpoint and two key secondary objectives.

Although itolizumab did not improve response rates at Day 29 for patients with acute GVHD, the therapy showed significant ...

Per the study protocol, patients received itolizumab within 3-days of the first administration of high-dose corticosteroids with a treatment period from Days 1-99, and a follow-up period from Days 100 ...

Equillium Inc. is forging ahead with regulatory plans for itolizumab in first-line treatment of patients with acute graft-vs.-host disease (GVHD), despite a phase III disappointment. Shares of the La ...

Equillium (NASDAQ:EQ – Get Free Report) is expected to be posting its quarterly earnings results before the market opens on Monday, March 24th. Analysts expect Equillium to post earnings of ($0.22) ...

Equillium's Phase 3 EQUATOR study found no significant difference in CR or ORR at Day 29 between itolizumab and placebo in aGVHD treatment. Itolizumab showed statistical significance in longer ...

The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the ...